Derek J Smith
University of Cambridge
H-index: 63
Europe-United Kingdom
Top articles of Derek J Smith
The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity
Emerging microbes & infections
2024/12/31
Immune imprinting revealed by SARS-CoV-2 Omicron infection prior to vaccination
2024/4/15
Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster
The Journal of Infectious Diseases
2024/3/15
Derek J Smith
H-Index: 38
Assessment of the antigenic evolution of a clade 6B. 1 human H1N1pdm influenza virus revealed differences between ferret and human convalescent sera
Ebiomedicine
2024/3/1
Global variation in prior exposure shapes antibody neutralization profiles of SARS-CoV-2 variants up to BA. 2.86
bioRxiv
2024
Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
bioRxiv
2023
Derek J Smith
H-Index: 38
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA. 1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
The Journal of infectious diseases
2023/12/15
Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
bioRxiv
2023
Characterization of A/H7 influenza virus global antigenic diversity and key determinants in the hemagglutinin globular head mediating A/H7N9 antigenic evolution
Mbio
2023/10/31
Derek J Smith
H-Index: 38
Immunogenicity of the BA. 1 and BA. 4/5 Bivalent Boosts: A Brief Report of Preliminary Results from the COVAIL Randomized Clinical Trial (preprint)
2023
Mapping SARS-CoV-2 antigenic relationships and serological responses
Science
2023/10/6
Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
bioRxiv
2023/9/27
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Nature medicine
2023/9
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.
2023/8/26
Derek J Smith
H-Index: 38
Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial
Clinical Infectious Diseases
2023/8/15
Richard Rupp
H-Index: 8
Derek J Smith
H-Index: 38
Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial
Research Square
2023/5/5
Nadine Rouphael
H-Index: 28
David Diemert
H-Index: 22
Susan Little
H-Index: 44
Evan Anderson
H-Index: 37
Richard Novak
H-Index: 24
Richard Rupp
H-Index: 8
Lisa Jackson
H-Index: 16
Lilly Immergluck
H-Index: 10
Dahlene Fusco
H-Index: 16
Stephen Walsh
H-Index: 8
Thomas Martin
H-Index: 9
Satoshi Kamidani
H-Index: 6
Michael Smith
H-Index: 19
Anna Wald
H-Index: 51
Mark Mulligan
H-Index: 32
David Stephens
H-Index: 26
Heather Hill
H-Index: 12
Jim Albert
H-Index: 17
Sam Wilks
H-Index: 5
Derek Smith
H-Index: 10
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Emerging Infectious Diseases
2023/5
Antigenic mapping of emerging SARS-CoV-2 omicron variants BM. 1.1. 1, BQ. 1.1, and XBB. 1
The Lancet Microbe
2023/5/1
Derek J Smith
H-Index: 38
Immunogenicity of the BA. 1 and BA. 4/BA. 5 SARS-CoV-2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial
medRxiv
2023/3/31
Richard Rupp
H-Index: 8
Derek J Smith
H-Index: 38
Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand
PLoS Pathogens
2022/5/2
